July 13, 2023 07:16 AM EDT

From hours to minutes? Genentech says Ocrevus subcutaneous formulation works just as well as IV

Amber Tong

To receive Roche’s multiple sclerosis drug Ocrevus, patients currently have to sit through two to four hours of infusion every six months. A year ago …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

From hours to minutes? Genentech says Ocrevus subcutaneous formulation works just as well as IV

Amber Tong

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

From hours to min­utes? Genen­tech says Ocre­vus sub­cu­ta­neous for­mu­la­tion works just as well as IV

Amber Tong

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

From hours to minutes? Genentech says Ocrevus subcutaneous formulation works just as well as IV

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA